NasdaqGM:VCYTBiotechs
Veracyte Taps Kevin Haas To Guide AI Push And Undervalued Shares
Veracyte, NasdaqGM:VCYT, has appointed Kevin Haas, Ph.D., as Chief Development and Technology Officer in a newly created executive role.
Dr. Haas will oversee assay development, software, AI, and next generation informatics across Veracyte's product pipeline.
The move reflects Veracyte's focus on whole genome MRD and multi omics applications across its global portfolio.
Veracyte's share price stands at $32.94, with a return of 60.1% over the past 3 years and a 2.2% decline over the past...